New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 2, 2013
15:57 EDTKYTHKythera announces positive interim results from SMF study
KYTHERA Biopharmaceuticals announced positive interim results from a Phase IIIb, multi-center, open-label study (ATX-101-11-26) to evaluate the safety and efficacy of ATX-101, an investigational injectable drug for the reduction of unwanted submental fat, SMF, commonly known as double chin. The results, presented at the Late Breaking Research Symposium at the 71st American Academy of Dermatology (AAD) Annual Meeting in Miami Beach, Fla., found that ATX-101 is well-tolerated and may be effective in reducing SMF by both clinician and patient reported outcome measures. The ATX-101 global clinical development program has enrolled more than 2,500 total patients, of which more than 1,500 have been treated with ATX-101.
News For KYTH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 10, 2015
11:47 EDTKYTHKYTHERA rallies after BofA/Merrill reinstates with Buy, $66 target
BofA/Merrill this morning reinstated coverage of KYTHERA Biopharmaceuticals with a Buy rating and $66 price target. The firm believes the company's ATX-101 has "significant" sales potential for the treatment of double chin. If approved, ATX-101 will be the first drug indicated for double chin, BofA/Merrill noted, and the first minimally invasive option for patients to reduce chin size. Shares of KYTHERA are up $1.87 to $48.87 in midday trading.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use